TD Cowen Raises Eli Lilly Price Target to $1,250

Analysts cite strong performance and growth potential for the pharmaceutical company.

Jan. 30, 2026 at 10:15am

Got story updates? Submit your updates here. ›

Analysts at TD Cowen have raised their price target for Eli Lilly and Company (NYSE:LLY) from $960 to $1,250, citing the pharmaceutical company's strong performance and growth potential. The new price target represents a potential upside of 21.89% from the company's previous close. Several other brokerages have also increased their price targets for Eli Lilly in recent months, reflecting optimism about the company's outlook.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, with a diverse portfolio of drugs and a strong research and development pipeline. The increased price targets from analysts suggest growing confidence in the company's ability to continue delivering strong financial results and shareholder value.

The details

TD Cowen raised its price target on Eli Lilly from $960 to $1,250 and maintained a 'buy' rating on the stock. The new price target points to a potential upside of 21.89% from the company's previous close. Other brokerages, including Daiwa Capital Markets, Morgan Stanley, JPMorgan Chase & Co., Wells Fargo & Company, and Wolfe Research, have also increased their price targets for Eli Lilly in recent months, reflecting the company's strong performance and growth potential.

  • The new price target was issued by TD Cowen on January 30, 2026.

The players

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. Eli Lilly researches, develops, manufactures, and commercializes a broad range of medicines and therapies for patients worldwide.

TD Cowen

A financial services firm that provides investment banking, securities, and wealth management services.

Got photos? Submit your photos here. ›

The takeaway

The increased price targets from multiple analysts suggest that Eli Lilly's strong performance and growth potential are being recognized by the investment community, which could lead to further gains for the company's stock.